阻抗素是一種衍生自脂肪組織的脂肪激素(adipocytokine)，研究顯示阻抗素不只是與胰島素阻抗性有關，也可能與血管活化及動脈硬化有關，會直接影響內皮細胞和血管的功能。本研究欲進行血漿中阻抗素濃度及基因型是否與新陳代謝症候群及腦血管疾病有相關性，以探討阻抗素在國人健康及疾病之影響。
本研究收集缺血性腦中風病人112位以及110位健康族群來進行生理、生化、高敏感性C反應蛋白及血漿中阻抗素濃度之分析;另收集缺血性腦中風病人594位以及799位健康族群分析阻抗素3’端非轉譯區+ 62 G/A基因多型性的分佈。阻抗素血漿濃度測定使用酵素免疫分析法(EIA)分析，阻抗素3’端非轉譯區+62 G/A基因型以聚合

Resistin is an adipocytokine derived from adipose tissue. Studies showed that resistin is not only related to insulin resistance, but also possibly an important factor related to activating of inflammation and atherosclerosis. It influences the endothelial cells and the function of vessel. To investigate whether or not resistin play a role in the metabolic syndrome and ischemic stroke. we examined the plasma resistin concentrations as well as the 3’ untranslated region +62 G/A polymorphism of resistin gene in a Taiwan population.
In the first part of this study, 112 patients with ischemic cerebral vascular disease and 110 healthy subjects were included and analyses of demographic and biochemical parameter, high sensitive C-reactive protein and plasma resistin concentration measurements were performed. In the second part, 594 patients with ischemic cerebral vascular disease and 799 healthy control were examined for resistin 3’ untranslated region +62 G/A polymorphism. Resistin concentration was analyzed by EIA method, and resistin 3’ untranslated region +62 G/A polymorphism was done by PCR and RFLP.
The mean plasma resistin concentration of 112 patients with ischemic cerebral vascular disease was significantly lower than that of the 110 controls (32 ± 59.7 ng/ml and 55.7 ± 82.5 ng/ml, p < 0.001).When the concentration of resistin was divided into 4 groups and analyzed as continuous variable, it was found that decreased plasma resistin concentration is associated with increased risk of ischemic cerebral vascular disease. After the multiple adjustment by logistic analysis, the adds ratio for the first, second and third quadrate were 7.8, 5.0 and 0.1, respectively).
The genotype analysis of 594 patients with ischemic cerebral vascular disease and 799 healthy controls show that the resistin genotype was related statistically to the risk of ischemic stroke. In multiple regression analysis, resistin 3’ untranslated region +62 G/A polymorphism was significantly associated with diastolic blood pressure (GA + AA : GG = 142.2 ± 19.2 : 139.3 ± 20.7 mmHg, p = 0.044) and fasting plasma sugar (GA + AA : GG : 83.4 ± 13.1 : 81.1 ± 13.1 mg/dl , p = 0.005).
Our results indicated that resistin may be related to metabolic syndrome and ischemic cerebral vascular disease and possibly play a role in the development of atherosclerosis.

目錄
中文摘要……………………………………………………p.1
英文摘要……………………………………………………p.3
緒論…………………………………………………………p.5
研究目的……………………………………………………p.15
實驗材料及方法……………………………………………p.16
研究結果……………………………………………………p.30
討論…………………………………………………………p.34
結論…………………………………………………………p.38
參考文獻……………………………………………………p.39
圖表…………………………………………………………p.48

1. Huang ZS, Chiang Tl, Lee TK. Stroke prevalence in Taiwan: Fings
from the 1994 National Health Interview Survey. Stroke 1997;28:
1579-1584.

2. Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK, Chen RC, Yip PK. Subtypes and case-fatality rates of stroke: a hospital-based stroke registry in Taiwan (SCAN-IV). J Neurol Sci 1998;156:220-226.

3. Sullivan DR: Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view: visceral obesity. Asia Pacific J Clin Nutr 2001;10:82-84.

4. Manson JE, Colditz GA, Stampfer MJ, Willet WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-1147.

5. Stamler J, Vasccaro, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.

6. Kaukua J, Turpeinen A, Uusitupa M, Niskanen L. Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking. Diabetes Obes Metab 2001;3:17-23.
7. Isomaa B, Amgren P, Tuomi, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.

8. Kalff KG, Maya-Pelzer P, Andexer A, Deuber HJ. Prevalence of the metabolic syndrome in military and civilian flying personnel. Aviat Space Environ Med.1999;70:1223-1226.

9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-359.

10. 國民健康局2002年委託台灣公共衛生學會進行臺灣地區高血糖、高血脂、高血壓盛行率。http://www.ettoday.com/2005/03/24/327-1768755.htm

11. Mykkaren L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease
risk factors as predictor of type (non-insulin dependent) diabetes mellitus in elderly subjects. Diabetologia 1993;36:553-559.

12. Hsieh MC, Lin SR, Chen HC, Lin JN, Shin SJ. Higher frequency of
apolipoprotein E2 allele in type 2 diabetic patients with nephropathy
in Taiwan. J Nephrol 2002;15:368-373.

13. Spath, P. L. Clinical paths: An outcomes management tool. In P.L. Spath
Clinical Paths: Tools For Ouctomes Management 1994;p1-24. American
Hospital Publishing, Inc.

14. Zimmet P, Alberti KG: The Changing face of macrovascu1ar
disease in noninsulin dependent diabetes mellitus in different cultures: an epidemic in progress. Lancet 1997;350 Suppl 1:SI 1-4.

15. Haffner SM, Stem MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confmned prediabetic individuals. Dose the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898

16. Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest 2002;25:
855-861.

17. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white
adipose tissue as an endocrine and secretory organ. Proc Nutr Sci
2001;60:329-339.

18. Lewis GF, Carpentier FA, Adeli K, Giacca A. Disordered fat storage and mobilization in pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
19..Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.

20. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by PPARγ agonists.J Biol Chem 2001; 276:25651-25653.

21.McTernan PC, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN,
Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002;87:2407.

22.Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas
D, antzoros CS. Body fat mass and macronutrient intake in relation to
circulating soluble leptin receptor, free leptin index, adiponection, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730-1736.

23. Savage DB,Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferators-activated receptor-gamma action in humans. Diabetes 2001;50:2199-2202.

24. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-476.

25. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by
human adipose tissue explans in primary culture. Biochem Biophys Res Commun 2003;300:674-678.

26. Jove M, Planavila A, Cabrero A, Novell F, Ros E, Zambon D, Laguna JC, Carrera MV. Reductions in plasma choleslerol levels after fenofibrate treatment are negatively correlated with resistin expression in humman adipose tissue. Metabolism 2003;52:351-355.

27. Steppan CM, Lazar MA. Resistin and obesity-associated insulin
resistance, Trends Endocrinol Metab 2002;13:18-23.

28. Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE. Cell type-specificexpression and coregulation of murine resistin and resistin like molecule-alpha in adipose tissue. Mol Endocrinol 2002; 16: 1920-1930.

29. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T. Hunoral regulatin of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51:1737-1744.

30. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-LI adipocytes. Biochem Biophys Res Commun 2001;288:1027-1031.

31. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.

32. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes. FEBS Lett 2001;500:60-63.

33. Karlander SG, Khan A, Wajngot A, Wajngot A, Torring O, Vranic M, Efendic S. Glucose turnover in hyperthyroid patients with normal glucose tolerance. J Clin Endocrinol Metab 1989;68:780-786.

34. Subodh Verma, MD, PhD;Shu-Hong Li, MSc; Chao-Hung Wang, MD; Paul W. M. Fedak, MD; Ren-Ke Li, MD, PhD; Richard D. Weisel, MD; Donald A.G. Mickle, MD. Resistin promotes endothelial cell activation Further Evidence of adipokine-endothelial interaction. Circulation 2003;
108:736-740.

35. Tan Ms, Chang SY, Chang DM, Tsai JC, Lee YJ. Association of resistin gene 3’-untranslated region +62G→A polymorphism with type2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab 2003;88:1258-1263.

36. Osawa H, Onuma H, Murakami A, Ochi M, Nishimiya T, Kato K, Shimizu I, Fujii Y, Ohashi J, Makino H. Systematic search for single nucleotide polymorphisms in the resistin gene:the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type2 diabetes.Diabetes. 2002;51:863-866.

37. Sentinelli F, Romeo S, Arca M, Filippi E, Leonetti F, Banchieri M, Di Mario U, Baroni MG. Human resistin gene, obesity, and type2 diabetes: mutation analysis and population study. Diabetes;51:860-862.

38. Pizzuti A, Argiolas A, Di Paola R, Baratta R, Rauseo A, Bozzali M, Vigneri R, Dallapiccola B, Trischitta V, Frittitta L. An ATG repeat in the 3’-untranslated region of the human resistin gene is associated with a decreased risk of insulin resistance. J Clin Endocrinol Metab 2002;87: 4403-4406.

39. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87: 2520-2524.

40. Engert JC, Vohl MC, Williams SM, Lepage P, Loredo-Osti JC, Faith J, Dore C, Renaud Y, Burtt NP, Villeneuve A, Hirschhorn JN, Altshuler D, Groop LC, Despres JP, Gaudet D, Hudson TJ. 5’ flanking variants of resistin are associated with obesity. Diabetes 2002;51:1629-1634.

41. Ma X, Warram JH, Trischitta V, Doria A. Genetic variants at the resistin locus and risk of type2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87:4407-4410.

42. Urbanek M, Du Y, Silander K, Collins FS, Steppan CM, Strauss JF 3rd, Dunaif A, Spielman RS, Legro RS. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes 2003;52:214- 217.

43. Kunnari A, Ukkoia O, Kesaniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabetic Medicine 2005;22:583-589.

44. Cao H, Hegele RA. Single nucleotide polymorphisms of the resistin (RSTN) gene. J Hum Genet. 2001;46:553-555.

45. Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL.
Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochemical
and Biophysical Research Communications 2002;296:383-387.

46. Kazuhiro Takahashi, Kazuhito Totsune, Masahiko Sone, Kumi Kikuchi, Osamu Murakami. Effects of adipokines on expression of adrenomedullin and endothelin-1 in cultured vascular endothelial cells. Peptides 2005; 26:845-851.

47. Soazig Le Lay, Jeremie Boucher, Astrid Rey, Isabelle Castan-Laurell, Stephane Krief, Pascal Ferre, Philippe Valet, and Isabelle Dugail. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochemical and Biophysical Research Communications 2001;289:564-567.

48. Furuhashi M, Ura N, Higashiura K, Murakami H, Shimamoto K. Circulating resistin levels in essential hypertension. Clin Endocrinol. 2003;59:507-510.

49. Jennifer H. Lee, Jean L. Chan, Nikos Yiannakouris, Meropi Kontogianni, Elizabeth Estrada, Richard Seip, Christine Orlova and Christos S. Mantzoros. Circulating Resistin Levels Are Not Associated with Obesity or Insulin Resistance in Humans and Are Not Regulated by Fasting or Leptin Administration: Cross-Sectional and Interventional Studies in Normal, Insulin-Resistant, and Diabetic Subjects. J Clin Endocrinol Metab. 2003;88:4848-4856.

50. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331-335.